Antibody-Drug Conjugates (ADCs) Derived from Interchain Cysteine Cross-Linking Demonstrate Improved Homogeneity and Other Pharmacological Properties over Conventional Heterogeneous ADCs

Christopher R. Behrens, Edward H. Ha, Lawrence L. Chinn, Simeon Bowers, Gary Probst, Maureen Fitch-Bruhns, Jorge Monteon, Amanda Valdiosera, Abel Bermudez, Sindy Liao-Chan, Tiffany Wong, Jonathan Melnick, Jan Willem Theunissen, Mark R. Flory, Derrick Houser, Kristy Venstrom, Zoia Levashova, Paul Sauer, Thi Sau Migone, Edward H. Van Der HorstRandall L. Halcomb, David Y. Jackson

Research output: Contribution to journalArticle

67 Scopus citations

Abstract

Conventional antibody-drug conjugates (ADCs) are heterogeneous mixtures of chemically distinct molecules that vary in both drugs/antibody (DAR) and conjugation sites. Suboptimal properties of heterogeneous ADCs have led to new site-specific conjugation methods for improving ADC homogeneity. Most site-specific methods require extensive antibody engineering to identify optimal conjugation sites and introduce unique functional groups for conjugation with appropriately modified linkers. Alternative nonrecombinant methods have emerged in which bifunctional linkers are utilized to cross-link antibody interchain cysteines and afford ADCs containing four drugs/antibody. Although these methods have been shown to improve ADC homogeneity and stability in vitro, their effect on the pharmacological properties of ADCs in vivo is unknown. In order to determine the relative impact of interchain cysteine cross-linking on the therapeutic window and other properties of ADCs in vivo, we synthesized a derivative of the known ADC payload, MC-MMAF, that contains a bifunctional dibromomaleimide (DBM) linker instead of a conventional maleimide (MC) linker. The DBM-MMAF derivative was conjugated to trastuzumab and a novel anti-CD98 antibody to afford ADCs containing predominantly four drugs/antibody. The pharmacological properties of the resulting cross-linked ADCs were compared with analogous heterogeneous ADCs derived from conventional linkers. The results demonstrate that DBM linkers can be applied directly to native antibodies, without antibody engineering, to yield highly homogeneous ADCs via cysteine cross-linking. The resulting ADCs demonstrate improved pharmacokinetics, superior efficacy, and reduced toxicity in vivo compared to analogous conventional heterogeneous ADCs.

Original languageEnglish (US)
Pages (from-to)3986-3998
Number of pages13
JournalMolecular Pharmaceutics
Volume12
Issue number11
DOIs
StatePublished - Nov 2 2015

Keywords

  • ADC
  • CD98
  • DAR
  • Her2
  • MMAF
  • antibody-drug conjugate
  • auristatin
  • bifunctional
  • conjugation
  • cysteine
  • dibromomaleimide
  • disulfide
  • hinge
  • homogeneous
  • interchain
  • linker
  • maleimide
  • site-specific
  • trastuzumab

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmaceutical Science
  • Drug Discovery

Fingerprint Dive into the research topics of 'Antibody-Drug Conjugates (ADCs) Derived from Interchain Cysteine Cross-Linking Demonstrate Improved Homogeneity and Other Pharmacological Properties over Conventional Heterogeneous ADCs'. Together they form a unique fingerprint.

  • Cite this

    Behrens, C. R., Ha, E. H., Chinn, L. L., Bowers, S., Probst, G., Fitch-Bruhns, M., Monteon, J., Valdiosera, A., Bermudez, A., Liao-Chan, S., Wong, T., Melnick, J., Theunissen, J. W., Flory, M. R., Houser, D., Venstrom, K., Levashova, Z., Sauer, P., Migone, T. S., ... Jackson, D. Y. (2015). Antibody-Drug Conjugates (ADCs) Derived from Interchain Cysteine Cross-Linking Demonstrate Improved Homogeneity and Other Pharmacological Properties over Conventional Heterogeneous ADCs. Molecular Pharmaceutics, 12(11), 3986-3998. https://doi.org/10.1021/acs.molpharmaceut.5b00432